<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908475</url>
  </required_header>
  <id_info>
    <org_study_id>M20-326</org_study_id>
    <secondary_id>2020-005512-21</secondary_id>
    <nct_id>NCT04908475</nct_id>
  </id_info>
  <brief_title>Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy</brief_title>
  <official_title>A Phase 3b Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that&#xD;
      results in thick, red, scaly plaques. This study will assess how safe and effective&#xD;
      risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis.&#xD;
      Adverse events and change in disease symptoms will be monitored.&#xD;
&#xD;
      Risankizumab (Skyrizi) and apremilast are approved drugs for the treatment of moderate to&#xD;
      severe PsO. Approximately 330 participants with moderate plaque psoriasis (PsO) will be&#xD;
      enrolled across approximately 55 sites globally.&#xD;
&#xD;
      The study has 2 periods : Period A from Baseline to Week 16, and Period B, from Week 16 to&#xD;
      Week 52. In Period A, participants will be randomly placed into 2 groups to receive either&#xD;
      subcutaneous risankizumab or oral apremilast for 16 weeks. In Period B, participants who&#xD;
      received apremilast in Period A will again be randomly assigned to 1 of the 2 groups to&#xD;
      receive either risankizumab or apremilast for 36 weeks. At weeks 28 and 40, participants&#xD;
      considered non-responders to apremilast based on their psoriasis score will be offered to&#xD;
      receive risankizumab.&#xD;
&#xD;
      There may be a higher burden for participants in this study compared to usual standard of&#xD;
      care. Participants will attend regular visits per routine clinical practice. The effect of&#xD;
      the treatment will be checked by medical assessments, checking for side effects, and&#xD;
      questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">April 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population in Period A (ITT_A)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at least 2-grade Improvement From Baseline in Intent to Treat Population in Period A (ITT_A)</measure>
    <time_frame>Week 16</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving PASI 90 in Intent to Treat Population for Period B Non-Responders (ITT_B_NR)</measure>
    <time_frame>Week 52</time_frame>
    <description>The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI From Baseline) in Intent to Treat Population in Period A (ITT_A)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 75 in Intent to Treat Population for Period B Non-Responders (ITT_B_NR)</measure>
    <time_frame>Week 52</time_frame>
    <description>The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at least 2-grade Improvement From Baseline in Intent to Treat Population for Period B Non-Responders (ITT_B_NR)</measure>
    <time_frame>Week 52</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Risankizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive risankizumab Dose A in Period A and Period B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2a: Apremilast/Risankizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive apremilast Dose A in Period A followed by risankizumab Dose A in Period B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2b: Apremilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive apremilast Dose A in Period A and Period B. Non-responders at Week 28 and Week 40 will be offered to receive risankizumab Dose A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risankizumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Arm 1: Risankizumab</arm_group_label>
    <arm_group_label>Arm 2a: Apremilast/Risankizumab</arm_group_label>
    <arm_group_label>Arm 2b: Apremilast</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>Skyrizi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Oral Tablets</description>
    <arm_group_label>Arm 2a: Apremilast/Risankizumab</arm_group_label>
    <arm_group_label>Arm 2b: Apremilast</arm_group_label>
    <other_name>Otezla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Candidates for systemic therapy with moderate chronic plaque psoriasis (PsO) (with or&#xD;
        without psoriatic arthritis) at Screening and Baseline for at least 6 months prior to&#xD;
        Baseline defined as:&#xD;
&#xD;
          -  Body Surface Area (BSA) &gt;= 10% and &lt;= 15%; and&#xD;
&#xD;
          -  Psoriasis Area and Severity Index (PASI) &gt;= 12; and&#xD;
&#xD;
          -  Static Physician Global Assessment (sPGA) = 3 (moderate) based on a 5-point scale (0&#xD;
             to 4).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has any form of PsO other than chronic plaque PsO (e.g., pustular PsO,&#xD;
             palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic, or guttate PsO).&#xD;
&#xD;
          -  History of current drug-induced PsO or a drug-induced exacerbation of pre-existing&#xD;
             psoriasis.&#xD;
&#xD;
          -  History of active ongoing inflammatory skin diseases other than PsO and psoriatic&#xD;
             arthritis that could interfere with the assessment of PsO (e.g., hyperkeratotic&#xD;
             eczema).&#xD;
&#xD;
          -  Prior exposure to risankizumab or apremilast.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Total Skin and Beauty Derm Ctr /ID# 233793</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates - Glendale /ID# 229266</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance Dermatology and MOHs /ID# 229224</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Health /ID# 229133</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Academic Centers Research and Education /ID# 229235</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research - Largo /ID# 233792</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research /ID# 228946</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 229135</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology /ID# 228945</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin, LLC /ID# 229010</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Epiphany Dermatology of Kansas LLC /ID# 229221</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DermAssociates /ID# 229016</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Company /ID# 229136</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center /ID# 229215</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-3046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MediSearch Clinical Trials /ID# 229269</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, LLC /ID# 229225</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Dermatology of the Midlands /ID# 229009</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144-1105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey /ID# 228943</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center /ID# 229240</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wright State Physicians - Fairborn /ID# 230051</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324-2640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center /ID# 233462</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc /ID# 229264</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology /ID# 230118</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies - Houston (Binz) /ID# 229272</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004-8097</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies /ID# 229263</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research /ID# 229220</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beacon Dermatology Inc /ID# 230121</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3E 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc. /ID# 230337</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research /ID# 230480</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karma Clinical Trials /ID# 230339</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Resea /ID# 230120</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research /ID# 230119</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. S.K. Siddha Medicine Professional Corporation /ID# 230416</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research /ID# 230336</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc. /ID# 230334</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 2V1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de recheche dermatologique du Quebec Metropolitain /ID# 230478</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen /ID# 229433</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt /ID# 229431</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster /ID# 229432</name>
      <address>
        <city>Munster</city>
        <state>Niedersachsen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DermaKiel Allergie und Haut Centrum /ID# 229630</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24148</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim /ID# 231504</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus /ID# 230245</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera /ID# 229445</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MENSINGDERMA research GmbH /ID# 229435</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatologische Gemeinschaftspraxis Mahlow /ID# 229434</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 229075</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center /ID# 231901</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 229620</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 229074</name>
      <address>
        <city>Petakh Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermed Centrum Medyczne Sp. z o.o /ID# 229051</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>High-Med Przychodnia Specjalistyczna /ID# 229023</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royalderm Agnieszka Nawrocka /ID# 228973</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-962</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniczny Szpital Wojewodzki Nr 1 Im.Fryderyka Chopina W Rzeszowie /Id# 229022</name>
      <address>
        <city>Rzeszów</city>
        <state>Podkarpackie</state>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 229053</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno-Badawcze /ID# 228971</name>
      <address>
        <city>Elblag</city>
        <state>Warminsko-mazurskie</state>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Risankizumab</keyword>
  <keyword>ABBV-066</keyword>
  <keyword>Skyrizi</keyword>
  <keyword>Apremilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

